Exelixis purchased an exclusive license for Insilico Medicine’s ISM3091 inhibitor for $80 million, outbidding at least four other companies. Insilico founder Alex Zhavoronkov selected Exelixis after being impressed by the company’s successful development of the cancer drug Cabometyx. Exelixis will also make additional payments for meeting development, commercial and sales-based milestones.
Columbia University Irving Medical Center pays $600K in data breach lawsuit settlement
In May 2024, DataBreaches logged an incident on our worksheets that involved the Columbia University Irving Medical Center in New York. The incident had been
